0

Erythrosin B Is a Potent and Broad-Spectrum Orthosteric Inhibitor of the Flavivirus NS2B-NS3 Protease

Zhong Li, Srilatha Sakamuru, Ruili Huang, Matthew Brecher, Cheri A Koetzner, Jing Zhang, Haiying Chen, Cheng-Feng Qin, Qing-Yu Zhang, Jia Zhou, Laura D Kramer, Menghang Xia, Hongmin Li

Antiviral Res. 2018 Feb;150:217-225.

PMID: 29288700

Abstract:

Many flaviviruses, such as Zika virus (ZIKV), Dengue virus (DENV1-4) and yellow fever virus (YFV), are significant human pathogens. Infection with ZIKV, an emerging mosquito-borne flavivirus, is associated with increased risk of microcephaly in newborns and Guillain-Barré syndrome and other complications in adults. Currently, specific therapy does not exist for any flavivirus infections. In this study, we found that erythrosin B, an FDA-approved food additive, is a potent inhibitor for flaviviruses, including ZIKV and DENV2. Erythrosin B was found to inhibit the DENV2 and ZIKV NS2B-NS3 proteases with IC50 in low micromolar range, via a non-competitive mechanism. Erythrosin B can significantly reduce titers of representative flaviviruses, DENV2, ZIKV, YFV, JEV, and WNV, with micromolar potency and with excellent cytotoxicity profile. Erythrosin B can also inhibit ZIKV replication in ZIKV-relevant human placental and neural progenitor cells. As a pregnancy category B food additive, erythrosin B may represent a promising and easily developed therapy for management of infections by ZIKV and other flaviviruses.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP16423680 Erythrosin B Erythrosin B 16423-68-0 Price
qrcode